Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Recher

Showing results (81-90 of 136) with videos related to

Pageof 14
Sort By:
Haematologica|September 22, 2011
High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) studyFrançois Vergez, Alexa S Green, Jerome Tamburini, et al.
Haematologica|December 10, 2020
Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical useAuriane Lesieur, Xavier Thomas, Olivier Nibourel, et al.
Oncotarget|April 16, 2016
Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemiaNorbert Vey, Jacques Delaunay, Giovanni Martinelli, et al.
American Journal of Hematology|August 23, 2012
Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS studyRomain Guièze, Pascale Cornillet-Lefebvre, Bruno Lioure, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMSArnaud Pigneux, Jean-Luc Harousseau, Francis Witz, et al.
Oncotarget|February 5, 2011
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndromeEmmanuel Raffoux, Audrey Cras, Christian Recher, et al.
British Journal of Haematology|June 19, 2013
Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-HématologiqueMichael Darmon, François Vincent, Laurent Camous, et al.
Blood|July 10, 2014
Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML IntergroupMarie-Anne Hospital, Thomas Prebet, Sarah Bertoli, et al.
Haematologica|February 26, 2015
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trialNicolas Boissel, Aline Renneville, Thibaut Leguay, et al.
Blood|May 31, 2011
Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalitiesAurore Perrot, Isabelle Luquet, Arnaud Pigneux, et al.
Pageof 14

Showing results (81-90 of 136) with videos related to

Sort By:
Pageof 14
Haematologica|September 22, 2011
High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) studyFrançois Vergez, Alexa S Green, Jerome Tamburini, et al.
Haematologica|December 10, 2020
Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical useAuriane Lesieur, Xavier Thomas, Olivier Nibourel, et al.
Oncotarget|April 16, 2016
Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemiaNorbert Vey, Jacques Delaunay, Giovanni Martinelli, et al.
American Journal of Hematology|August 23, 2012
Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS studyRomain Guièze, Pascale Cornillet-Lefebvre, Bruno Lioure, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMSArnaud Pigneux, Jean-Luc Harousseau, Francis Witz, et al.
Oncotarget|February 5, 2011
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndromeEmmanuel Raffoux, Audrey Cras, Christian Recher, et al.
British Journal of Haematology|June 19, 2013
Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-HématologiqueMichael Darmon, François Vincent, Laurent Camous, et al.
Blood|July 10, 2014
Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML IntergroupMarie-Anne Hospital, Thomas Prebet, Sarah Bertoli, et al.
Haematologica|February 26, 2015
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trialNicolas Boissel, Aline Renneville, Thibaut Leguay, et al.
Blood|May 31, 2011
Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalitiesAurore Perrot, Isabelle Luquet, Arnaud Pigneux, et al.
Pageof 14